MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
BOSTON, April 11, 2024 /PRNewswire/ -- MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Frank Neumann, M.D., Ph.D., will join the Company as Entrepreneur Partner. In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.
波士頓，2024年4月11日 /PRNewswire/ — 創建和投資尋求爲患者提供變革性療法的創新公司的生物技術投資公司MPM BioImpact今天宣佈，醫學博士弗蘭克·諾伊曼博士將以企業家合夥人的身份加入該公司。此外，諾伊曼博士將加入MPM BioImpact投資組合公司Orna Therapeutics擔任首席醫學官。
"Frank is an innovator and distinguished leader with a demonstrated history of success in CAR-based cell therapy and clinical advancement," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact. "His extensive experience advancing novel cell therapies and modalities will be valuable as we continue to broaden our investment initiatives and partnerships, building companies to transform patient outcomes."
MPM BioImpact管理合夥人安斯伯特·加迪克醫學博士表示：“弗蘭克是一位創新者和傑出領導者，在基於汽車的細胞療法和臨床進展方面有着良好的成功歷史。”“隨着我們繼續擴大投資計劃和合作夥伴關係，建立公司以改變患者預後，他在推進新型細胞療法和模式方面的豐富經驗將非常寶貴。”
MPM BioImpact Entrepreneur Partners are investor-operators who provide deep domain expertise in research and development, clinical strategy, intellectual property and commercialization, working with the firm's diverse team of scientists and investment professionals to develop therapies for diseases with high unmet needs. Dr. Neumann's deep clinical experience will serve to support MPM BioImpact's investment process and the advancement of its underlying portfolio companies.
MPM BioImpact Entrepreneur Partners是投資者兼運營商，他們在研發、臨床戰略、知識產權和商業化方面提供深厚的專業知識，與公司的多元化科學家和投資專業人員團隊合作，爲需求未得到滿足的疾病開發療法。諾伊曼博士的深厚臨床經驗將爲MPM BioImpact的投資流程及其標的投資組合公司的發展提供支持。
"I'm thrilled to join the MPM BioImpact ecosystem and contribute to its patient-focused mission," said Dr. Neumann. "The firm's scientific rigor and expertise in creating companies from the ground up has catalyzed the development of life-saving drugs. This is a very exciting opportunity to help pioneer novel, impactful therapies for patients in need."
諾伊曼博士說：“我很高興加入MPM BioImpact生態系統，爲其以患者爲中心的使命做出貢獻。”“該公司在從頭開始創建公司方面的嚴謹科學和專業知識催化了救生藥物的開發。這是一個非常激動人心的機會，可以幫助有需要的患者開拓新穎的、有影響力的療法。”
Dr. Neumann currently serves as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company, and previously held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and as Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, Dr. Neumann served as clinical development head for all of Takeda Pharmaceuticals cell therapy approaches globally, and held various leadership roles of increasing prominence, including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, he was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.
諾伊曼博士目前在吉利德旗下公司Kite擔任高級副總裁兼全球臨床開發主管，此前曾在Verastem, Inc.（也稱爲Verastem Oncology）擔任首席醫學官和藍鳥生物副總裁兼腫瘤學臨床研究主管。此外，諾伊曼博士曾擔任武田製藥全球所有細胞療法的臨床開發主管，並擔任過越來越重要的各種領導職務，包括兩種不同癌症療法的全球臨床負責人和醫療團隊負責人。在他職業生涯的早期，他是阿斯利康和賽諾菲安萬特腫瘤醫療團隊的成員。
In addition to his extensive industry experience, Dr. Neumann is board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine. He was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany. He earned his M.D. from the Heinrich Heine University and his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.
除了豐富的行業經驗外，諾伊曼博士還獲得了血液學/腫瘤學、內科和姑息治療醫學的董事會認證。他曾是德克薩斯大學醫學博士安德森癌症中心的研究學者，目前是德國杜塞爾多夫海因裏希·海涅大學的助理教授。他在海因裏希·海涅大學獲得醫學博士學位，在德國波恩的萊茵-弗里德里希-威廉大學獲得博士學位。
About MPM BioImpact
MPM BioImpact is a world-leading biotechnology investment firm with over 30 years of expertise creating and investing in innovative companies to deliver transformative therapies to patients. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors and leading scientists translate scientific discoveries into breakthrough medicines and potential cures. For more information, visit
關於 MPM BioImpact
MPM BioImpact是一家世界領先的生物技術投資公司，擁有超過30年的專業知識，致力於創建和投資創新公司，爲患者提供變革性療法。其由投資專業人士、企業家、顧問和頂尖科學家組成的經驗豐富、敬業的團隊將科學發現轉化爲突破性藥物和潛在的治療方法。欲了解更多信息，請訪問
SOURCE MPM BioImpact
來源 MPM BioImpact
譯文內容由第三人軟體翻譯。